How Will Abbott Labs (ABT) Purchase of CFR Pharmaceuticals Affect Its Stock?

NEW YORK (TheStreet) -- Abbott Laboratories (ABT) announced today that it will pay $2.9 billion to buy Santiago, Chile-based CFR Pharmaceuticals as it expands in Latin America.

Shares of Abbott are up 0.59% to $39.47

CFR Pharmaceuticals is in 15 Latin American markets and has over 1,000 products.

Must Read: Warren Buffett's 10 Favorite Growth Stocks

Abbott said CFR has a portfolio well-aligned with its current focuses in women's health, central nervous system, cardiovascular and respiratory diseases.

TheStreet Ratings team rates ABBOTT LABORATORIES as a Hold with a ratings score of C. TheStreet Ratings Team has this to say about their recommendation:

"We rate ABBOTT LABORATORIES (ABT) a HOLD. The primary factors that have impacted our rating are mixed some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and notable return on equity. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and weak operating cash flow."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

  • The current debt-to-equity ratio, 0.33, is low and is below the industry average, implying that there has been successful management of debt levels. Along with the favorable debt-to-equity ratio, the company maintains an adequate quick ratio of 1.07, which illustrates the ability to avoid short-term cash problems.
  • ABBOTT LABORATORIES's earnings per share declined by 35.3% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, ABBOTT LABORATORIES increased its bottom line by earning $1.50 versus $0.36 in the prior year. This year, the market expects an improvement in earnings ($2.21 versus $1.50).
  • The gross profit margin for ABBOTT LABORATORIES is rather high; currently it is at 57.53%. Regardless of ABT's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 7.15% trails the industry average.
  • Net operating cash flow has decreased to $336.00 million or 26.99% when compared to the same quarter last year. In addition, when comparing the cash generation rate to the industry average, the firm's growth is significantly lower.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed against the S&P 500 and did not exceed that of the Health Care Equipment & Supplies industry. The net income has significantly decreased by 31.1% when compared to the same quarter one year ago, falling from $544.66 million to $375.00 million.
  • You can view the full analysis from the report here: ABT Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Abbott Park, Illinois (NYSE: ABT) Abbott today announced a definitive agreement to acquire Latin American pharmaceutical company CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence and further expanding Abbott's presence in fast-growing markets. Under the terms of the agreement, Abbott will acquire the holding company that indirectly owns approximately 73 percent of CFR Pharmaceuticals and will conduct a public cash tender offer for all of the outstanding shares of CFR. Assuming all publicly-held shares are tendered, the total purchase price would be approximately $2.9 billion, plus the assumption of net debt of approximately $430 million.

This acquisition immediately establishes Abbott among the top 10 pharmaceutical companies in Latin America, further broadening Abbott's geographic presence across the region.

Abbott Park, Illinois (NYSE: ABT) Abbott today announced a definitive agreement to acquire Latin American pharmaceutical company CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence and further expanding Abbott's presence in fast-growing markets. Under the terms of the agreement, Abbott will acquire the holding company that indirectly owns approximately 73 percent of CFR Pharmaceuticals and will conduct a public cash tender offer for all of the outstanding shares of CFR. Assuming all publicly-held shares are tendered, the total purchase price would be approximately $2.9 billion, plus the assumption of net debt of approximately $430 million.

This acquisition immediately establishes Abbott among the top 10 pharmaceutical companies in Latin America, further broadening Abbott's geographic presence across the region.

Abbott Park, Illinois (NYSE: ABT) Abbott today announced a definitive agreement to acquire Latin American pharmaceutical company CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence and further expanding Abbott's presence in fast-growing markets. Under the terms of the agreement, Abbott will acquire the holding company that indirectly owns approximately 73 percent of CFR Pharmaceuticals and will conduct a public cash tender offer for all of the outstanding shares of CFR. Assuming all publicly-held shares are tendered, the total purchase price would be approximately $2.9 billion, plus the assumption of net debt of approximately $430 million.

This acquisition immediately establishes Abbott among the top 10 pharmaceutical companies in Latin America, further broadening Abbott's geographic presence across the region.

If you liked this article you might like

Roku, Amazon, Teladoc, Weyerhaeuser: 'Mad Money' Lightning Round

Roku, Amazon, Teladoc, Weyerhaeuser: 'Mad Money' Lightning Round

Volatility Is Still in Charge: Cramer's 'Mad Money' Recap (Friday, 2/9/18)

Volatility Is Still in Charge: Cramer's 'Mad Money' Recap (Friday, 2/9/18)

Cramer: 10 Points to Consider

Cramer: 10 Points to Consider

The 5 Best Dividend Aristocrats For 2018

The 5 Best Dividend Aristocrats For 2018

Lam Research: Cramer's Top Takeaways

Lam Research: Cramer's Top Takeaways